Latest News Home » News On March 7, 2024, the U.S. Food and Drug Administration (FDA) announced it has approved Bruton tyrosine kinase inhibitor (BTKi), zanubrutinib (Brukinsa, BeiGene USA, Inc.) with obinutuzumab for the treatment of adult patients with relapsed/refractory follicular lymphoma (FL) after two or more lines of systemic therapy. “New medicines can transform the way healthcare providers approach this type of blood cancer,” said Meghan Gutierrez, Chief Executive Officer of the Lymphoma Research Foundation. “We commend those who contribute to accelerating research for the benefi ..read more

Latest News Home » News Celebrating the Original ‘Chemo Diva’ Upon receiving a lymphoma diagnosis, it’s not uncommon to search for others like you who are going through a similar experience. That sense of community and support, of seeing your own story reflected to you, can provide much-needed encouragement and help you feel less alone. But what if you can’t easily find a community with stories of people who look like you? If you’re Tatiana Tate, founder of Chemo Divas Foundation, you create your own. Tatiana, a 30-year-old Black accounting professional based in Connecticut, started the Ch ..read more

Latest News Home » News Where Are They Now? Ryan Lynch, MD Dr. Ryan Lynch is a hematologist-oncologist at Fred Hutchinson Cancer Center. When did you become interested in the study of medicine? In lymphoma specifically? I had a great opportunity while I was in my residency at Washington University in St. Louis to work on a project examining outcomes of older patients with diffuse large B-cell lymphoma under the mentorship of Dr. Ken Carson. I had further mentorship during my hemeonc fellowship at Stanford working under Dr. Ranjana Advani. While at Stanford, I was able to work with one of ..read more

Latest News Home » News Advancing Cures and Developing the Next Generation of Lymphoma Researchers Growing up in Spoleto, Italy, Laura Pasqualucci, MD, loved classical music. While her appreciation for music led her to attend a conservatory to study the art form, it was ultimately her adoration for medicine that inspired her to dedicate her career to studying pathology. As a child, Pasqualucci visited the emergency clinic where her father worked, and the intellectual complexity and humanitarian aspects of medicine drew her in. Medicine runs deep in Pasqualucci’s family. Her father was a ph ..read more

Latest News Home » News Dear Friends of LRF, The Lymphoma Research Foundation (LRF) is defined by its tireless commitment to our mission: eradicating lymphoma and serving those who have been touched by this disease. With each breakthrough, we are one step closer to reaching these goals. In this issue of Pulse, we profile one of the innovative leaders responsible for such breakthroughs, Laura Pasqualucci, MD, Professor of Pathology and Cell Biology at the Institute for Cancer Genetics at Columbia University and a member of the Foundation’s prestigious Scientific Advisory Board (SAB). Dr. Pa ..read more

Latest News Home » News Updates from the 2023 American Society of Hematology Annual Meeting The Lymphoma Research Foundation (LRF) returned to the American Society of Hematology (ASH) Annual Meeting and Exposition, with 318 LRF-affiliated scientists, including past and present members of LRF’s world-leading Scientific Advisory Board (SAB) and grantees, contributing to an abstract presented at the conference. Widely regarded as the premier event in malignant and nonmalignant hematology, the ASH Meeting provides a critical forum for leading hematologists/oncologists to present their finding ..read more

Latest News Home » News ASH 2023: Increased Metabolism in High IRF4-Expressing Lymphoma Cells Limits the Availability of Glucose in the Tumor Microenvironment Cancer cells routinely reprogram cellular metabolism to improve their fitness, providing a selective advantage that supports growth and expansion. Researchers previously determined that increased expression of the protein IRF4 is associated with altered immune signaling and an immunosuppressive tumor microenvironment in follicular lymphoma (FL), which collectively correlate with poor prognosis. In the present study, presented by LRF ..read more

Latest News Home » News ASH 2023: Durable Responses Observed with Valemetostat Improved Outcomes in Second-Line Treatment of Large B-Cell Lymphoma in the Era of CAR T-Cell Therapies The treatment landscape of large B-cell lymphomas (LBCL) has changed dramatically in recent years, driven in part by the emergence of chimeric antigen receptor (CAR) T-cell therapies. To understand how these drugs have changed survival in patients with LBCL, investigators analyzed outcomes from the Lymphoma Epidemiology of Outcomes (LEO) Consortium for Real World Evidence (CReWE) study among participants with ..read more

Latest News Home » News ASH 2023: Durable Responses Observed with Valemetostat Tosylate Treatment in Relapsed/Refractory Peripheral T-Cell Lymphoma Treatment options for relapsed or refractory peripheral T-cell lymphoma (PTCL) are limited, and many patients experience an aggressive disease course. In the phase 2 VALENTINE-PTCL01 study, the safety and efficacy of the novel drug valemetostat tosylate – approved for the treatment of relapsed/refractory adult T-cell leukemia/ lymphoma (ATLL) in Japan – was investigated in patients with relapsed/refractory PTCL. Primary results from this study ..read more

Latest News Home » News ASH 2023: Overall Survival in Mantle Cell Lymphoma Has Improved in the Era of Targeted Therapies Mantle cell lymphoma (MCL) has historically been treated using combination chemoimmunotherapy followed by stem cell transplant and has been associated with poor survival outcomes. Within the last decade, a variety of targeted therapies have emerged for the treatment of MCL that have been shown to improve progression-free survival. The benefits of many of these therapies on overall survival (OS), however, has not been described. Investigators therefore sought to compare ..read more